Microsoft word - pl_portfolio.doc

Publications for which Dr. Novack was the medical writer
 Dell SJ, Hovanesian JA, Raizman MB, et al. Randomized comparison of postoperative use of hydrogel ocular bandage and collagen corneal shield for wound protection and patient tolerability after cataract surgery. J Cataract Refract Surg 2011;37:113-21.  Fea AM. Phacoemulsification versus phacoemulsification with micro-bypass stent implantation in primary open-angle glaucoma: randomized double-masked clinical trial. J Cataract Refract Surg 2010;36:407-12.  Lewis RA, Gross RL, Sall KN, Schiffman RM, Liu CC, Batoosingh AL, for the Ganfort® Investigators Group II. The safety and efficacy of Bimatoprost/Timolol fixed combination: A one-year double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J Glaucoma 2010;19:424-6.  Hommer A for the Ganfort® Investigators Group I: A double masked, randomized, parallel, comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension. Eur J Ophthalmol 2007;17(1): 53-62.  Spiegel D, Wetzel W, Haffner DS, Hill RA. Initial Clinical Experience With the Trabecular Micro-Bypass Stent in Patients With Glaucoma. Adv Ther 2007;24:161-70.  Robin AL, Covert D. Does Adjunctive Glaucoma Therapy Affect Adherence to the Initial Primary Therapy? Ophthalmology 2005;112:863-8.  Tan DTH, Lam DS, Chua WH, Ping DFS, Crockett RS for the Asian Pirenzepine Study Group. One-Year Multi-Center, Double-Masked, Placebo-Controlled, Parallel, Safety and Efficacy Study of 2% Pirenzepine Ophthalmic Gel in Children with Myopia. Ophthalmology 2005;112: 84-91.  Dubiner HB, Sircy MD, Landry T, Bergamini MVW, Silver LH, Turner FD, Robertson S, Andrew RM, Weiner A, Przydryga J. A comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44 hour period in patients with elevated intraocular pressure. Clin Ther 2004;26:84-91.  Kaback M, Geanon J, Katz G, Ripkin D, Przydryga J, and the S.T.A.R.T. Study Group. Ocular hypotensive efficacy of travoprost in patients unsuccessfully treated with latanoprost. Current Medical Research and Opinion 2004;20 (9): 1341-1345.  Bartlett JD, Niemann K, Houde B, et al. Safety and tolerability of pirenzepine ophthalmic gel in pediatric myopic patients. J Ocul.Pharmacol.Ther . 2003;19:271-279.  Alldredge BK, Venteicher R, Calderwood TS. Stability of diazepam rectal gel in ambulance-like environments. Am J Emerg Med 2002;20:88-91.  Cereghino JJ, Cloyd JC, Kuzniecky RI for the North American Diastat Study Group. Rectal Diazepam Gel for Treatment of Acute Repetitive Seizures in Adults. Arch Neurology 2002;59:1915-1920.  Konsil J, Dechasathian S, Mason DH, Jr., Stevens RE. Reanalysis of carbamazepine and carbamazepine-epoxide pharmacokinetics after multiple dosing of extended release formulation. J Pharm Pharm Sci 2002;5:169-75. pl_portfolio.doc /30 december 2010/-1  Nordmann JP, Mertz B, Yannoulis NC, et al. A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data(1). Am J Ophthalmol 2002;133:1-10.  Brown L, Bergen DC, Kotagal P, Groves L, Carson D. Safety of Diastat when given at larger-than-recommended doses for acute repetitive seizures. Neurology, 56:1112.  Demailly P, Allaire C, Trinquand C. Ocular hypotensive efficacy and safety of once daily carteolol alginate. Br J Ophthalmol 2001;85:921-4.  McLean, A., Browne S., Zhang Y., Slaughter E., Halstenson C., Couch R. The Influence of Food on the Bioavailability of a Twice-Daily Controlled Release Carbamazepine Formulation, J. Clin Pharmacol 2001;41 (2):183-186.  Shedden A, Laurence J, Tipping R, Timoptic-XE 0.5% Study Group. Efficacy and tolerability of timolol maleate ophthalmic gel-forming solution versus timolol ophthalmic solution in adults with open-angle glaucoma or ocular hypertension: A six-month, double-masked, multicenter study. Clin Ther 2001;25:440-50.  Barnebey HS, Kwok SY. The acceptance of switching patients from dorzolamide to brinzolamide. Clin Ther 2000; 22(10):1204-1212.  Grekin RC, Tope WD, Yarborough JM, et al. Electrosurgical Facial Resurfacing: A Prospective Multicenter Study of Efficacy and Safety . Arch Dermatol 2000;136:1309-16.  Jacobi FK, Kammann J, Jacobi KW, et al. Bilateral implantation of asymmetrical diffractive multifocal intraocular lenses. Arch Ophthalmol 1999;117:17-23.  Rowen S. Preoperative and postoperative medications used for cataract surgery. Curr  Steinert RF, Aker BL, Trentecost DJ, et al. A prospective comparative study of the AMO array zonal.progressive multifocal silicone intraocular lens and a monofocal intraocular lens. Ophthalmology 1999;106:1243-55.  Abelson M, Howes J, George M. The conjunctival provocation test model of ocular allergy: Utility for assessment of an ocular corticosteroid, loteprednol etabonate. J. Ocul. Pharmacol. Ther. 1998; 14:533-542.  Garnett WR, Levy B, McLean AM, Zhang Y, Couch RA, Rudnic EM, Belendiuk GW. Pharmacokinetic evaluation of twice-daily extended-release carbamazepine and four-times daily immediate-release carbamazepine in patients with epilepsy. Epilepsia 1998;39:274-279.  Groves L, Shellenberger MK, Davis CS. Tizanidine treatment of spasticity: A meta- analysis of controlled, double-blind studies comparing with baclofen and diazepam. Advance in Therapy 1998; 15:241-251.  Mirza WU, Rak IW, Thadani VM, Cereghino JJ, Garnett WR, Brown LM, et al. Six- month evaluation of Carbatrol (extended-release carbamazepine) in complex partial seizures. Neurology 1998; 51:1727-1729.  Stevens RE, Limsakun T, Evans G, Mason DH. Controlled, multidose, pharmacokinetic evaluation of two extended release carbamazepine formulations (Carbatrol and Tegretol-XR). J. Pharm Sci. 1998;87:1531-1534. pl_portfolio.doc /30 december 2010/-2  Asbell PA, Howes J, Loteprednol GPC Study Group II: A double-masked placebo- controlled, evaluation of the efficacy and safety of loteprednol etabonate in the treatment of contact-lens associated giant papillary conjunctivitis. CLAO J 1997;23:31-36.  Dell SJ, Shulman DG, Lowry GM, Loteprednol Allergic Conjunctivitis Study Group: A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate (LE) in the treatment of seasonal allergic conjunctivitis (SAC). Am J Ophthalmol 1997;123:791-797.  Friedlaender MH, Howes J, Loteprednol Etabonate GPC Study Group I: A double- masked, placebo-controlled, evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. Am J Ophthalmol 1997;123:455-464.  Ostrov CS, Sirkin SR, Deutsch WE, Masi RJ, Chandler JW, Lindquist TD. Ketorolac, prednisolone, and dexamethasone for postoperative inflammation. Clin Ther. 1997;19:259-272.  Robin AL. Ocular hypotensive efficacy and safety of a combined formulation of betaxolol and pilocarpine. Trans. Am. Ophthalmol. Soc. 1996;94:89-103.  Shin DH, Frenkel REP, David R, Cheetham JK, The Fluorometholone-Laser Trabeculoplasty Study Group: Effect of topical anti-inflammatory treatment on the outcome of laser trabeculoplasty. Am J Ophthalmol 1996;122:349-354.  Strahlman E, Tipping R, Vogel R, Dorzolamide Dose-Response Study Group: A six- week dose-response study of the ocular hypotensive effect of dorzolamide with a one-year extension. Am J Ophthalmol 1996;122:183-194.  Strahlman ER, Vogel R, Tipping R, Clineschmidt CM: The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure. The Dorzolamide Additivity Study Group. Ophthalmology 1996;103:1283-1293.  Harper DG, Chen CE, Friedlaender MH: Controlled comparison of two fluorometholone formulations in the antigen challenge model of allergic conjunctivitis. CLAO J 1995;21:256-260.  Lyden M, Applebaum HJ: Effect of ophthalmic metipranolol and timolol on exercise- induced tachycardia. J Glaucoma 1995;4:124-129.  Strahlman E, Tipping R, Vogel R, and the International Dorzolamide Study Group. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol and betaxolol. Arch Ophthalmol 1995;113:1009-1016.  Behrens-Baumann W, Kimmich F, Walt JG, Lue J: A comparison of the ocular hypotensive efficacy and systemic safety of 0.5% levobunolol and 2% carteolol. Ophthalmologica 1994;208:32-36.  Keates EU, Friedland BR, Stewart RH, Mandell AI for the American Carteolol Study Group. Carteolol hydrochloride: Controlled evaluations of its ocular hypotensive efficacy relative to its vehicle, and, in combination with pilocarpine, relative to timolol. J. Glaucoma 1994;3:315-322.  Notivol R, Martinez M, Bergamini MVW, Pranoprofen Study Group: Treatment of chronic nonbacterial conjunctivitis with a cyclo-oxygenase inhibitor or a corticosteroid. Am J Ophthalmol 1994;117:651-656. pl_portfolio.doc /30 december 2010/-3  Albracht DC, LeBlanc RP, Cruz AM, Lamping KA, Siegel LI, Stern KL, Kelley EP, Stoecker, JF. A double-masked comparison of betaxolol and dipivefrin for the treatment of elevated intraocular pressure. American Journal of Ophthalmology 1993; 116:307-313.  Barnebey HS, Robin AL, Zimmerman TJ, et al: The efficacy of brimonidine in decreasing elevations in intraocular pressure after laser trabeculoplasty. Ophthalmology 1993;100:1083-1099.  Blaydes JE, Kelley EP, Walt JG, DeGryse RE, Harper DG, Novack GD: Flurbiprofen 0.03% for the control of inflammation following cataract extraction by phacoemulsification. J Cataract Refract Surg 1993;19:481-487.  Chen CC, Takruri H, Duzman E: Enhancement of the ocular bioavailability of topical tobramycin with use of a collagen shield. J Cataract Refract Surg 1993;19:242-245.  Greenspan A, Herndon JH, Jr., Baker MD, Cheney T: Controlled evaluation of 0.05% desonide lotion and desonide cream in psoriasis. Curr Ther Res 1993;53:614-620.  Hadgraft J, Williams DG, Allan G: Azone: mechanisms of action and clinical effect, in Walters KA, Hadgraft J. (eds): Pharmaceutical skin penetration enhancement. New York, Marcel Dekker, 1993, pp 175-197.  Kessler C, Christ T: The incidence of uveitis in glaucoma patients using metipranolol. J  Laurence J, Holder D, Vogel R, et al: A double-masked, placebo-controlled evaluation of timolol in gel vehicle. J Glaucoma 1993;1993:177-182.  Mills OH, Dammers K, Berger R, Baker MD. Evaluating the irritancy of cleansers on photoaged skin. Presentation at the American Academy of Dermatology, December 1993.  Prawer SE, Katz HI, Herndon JH, Jr., Baker MD, Cheney T: Controlled, bilateral, comparative evaluation of 0.05% desonide lotion and desonide cream in eczematous dermatitis. Curr Ther Res 1993;53:607-613.  Wendel RT, Patel AC, Kelly NE, Salzano TC, Wells JW, Novack GD: Vitreous surgery for macular holes. Ophthalmology 1993;100:1671-1676.  Beehler CC, Stewart WC, MacDonald DK, et al. A comparison of the ocular hypotensive efficacy of twice-daily 0.25% levobunolol to 0.5% timolol in patients previously treated with 0.5% timolol. J Glaucoma 1992;1:237-242.  Collignon-Brach J. Long-term effect of ophthalmic -adrenoceptor antagonists on intraocular pressure and retinal sensitivity in primary open-angle glaucoma. Curr Eye Res 1992;11:1-3.  Demick S., Ohnsman C, Hodges B, et al. Field defects in diabetic patients [Letter].  Lowe NJ, Mobayen MM, Pincu FD, et al. Objective measurement of UVA Photoprotection in human epidermis. In Urbach F, ed. Biological responses to UVA radiation, Valdenmar Publ Co. Overland Park KS, 1992, pp 363-369.  Miller IM, Vogel R, Cook TJ, Wittreich J, and The Worldwide Norfloxacin Ophthalmic Study Group. Topically administered norfloxacin compared with topically administered gentamicin for the treatment of external ocular bacterial infections. Am J Ophthalmol 1992;113:638-644. pl_portfolio.doc /30 december 2010/-4  Miller IM, Wittreich JM, Cook T Vogel R for the Norfloxacin-Chloramphenicol Ophthalmic Study Group. The safety and efficacy of topical norfloxacin compared with chloramphenicol for the treatment of external ocular bacterial infections. Eye 1992;6:111-114.  Silverstone DE, Brint SF, Olander KW, et al. Prophylactic use of apraclonidine for intraocular pressure increase after Nd:YAG capsulotomies. Am J Ophthalmol 1992;113:401-405. Plus letter to the Editor: Am J Ophthalmol 1992;114:378-379.  Sturm A, Vogel R, Binkowitz B, Timolol-Pilocarpine Clinical Study Groups. A fixed combination of timolol and pilocarpine: Double-masked comparisons with timolol and pilocarpine. J Glaucoma 1992;1:7-13.  Weinreb RN, Jani R. A novel formulation of an ophthalmic beta-adrenoceptor antagonist.  Ernest PH, Kiessling LA, Lavery KT. Relative strength of cataract incisions in cadaver eyes. J Cataract Refract Surg 1991;17 (Suppl):668-671.  Kelly NE, Wendel RT. Vitreous surgery for idiopathic macular holes. Results of a pilot study. Arch Ophthalmol 1991;109:654-659. o This paper was #24 of the top 100 most frequently cited articles in ophthalmology journals (Ohba et al, Arch Ophthalmol 2007;125:952-60).  Savelsbergh-Fillette MP, Demailly P. Etude comparative du levobunolol et du timolol dans le traitment du glaucome chronique primitif a angle ouvert et de l'hypertension oculaire chronique. J Fr Ophtalmol 1988;11:587-90.  Pecori-Giraldi J, Boles-Carenini B, Virno M, et al. Double-blind study of bunolol versus timolol in open-angle glaucoma. Proceedings of the XXVth International Congress of Ophthalmology, Rome, May 4-10, 1986. Amsterdam: Kugler & Ghedini, 1987.  Stryz JR, Merte H-J. Drucksenkender effekt und nebenwirkungen von levobunolol- augentropfen 0,5% und 1,0%, verglichen mit timolol-augentropfen 0,5% bei patienten mit weitwinkelglaukomen. Klin Mbl Augenheilk 1985;187:537-44. pl_portfolio.doc /30 december 2010/-5

Source: http://www.pharmalogic.com/IMAGES/pl_portfolio.pdf